Premium
Comparison of the effects of moxifloxacin (0.5%) and gatifloxacin (0.3%) ophthalmic solutions on corneal sensitivity
Author(s) -
Torkildsen Gail,
French Susan,
Shapiro Aron,
Abelson Mark B
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a266-a
Subject(s) - gatifloxacin , moxifloxacin , placebo , medicine , ophthalmology , cornea , anesthesia , levofloxacin , antibiotics , alternative medicine , pathology , microbiology and biotechnology , biology
Purpose This study was designed to evaluate any changes in corneal sensitivity induced by the topical ophthalmic fluoroquinolone solutions moxifloxacin and gatifloxacin compared to placebo. Methods This contralateral, double masked, placebo controlled, three visit study enrolled healthy subjects with normal ocular health. Subjects were randomized to one of three treatment groups, which adhered to 10 days of QID dosing: moxifloxacin in one eye and placebo in the other, gatifloxacin in one eye and placebo in the other, or moxifloxacin in one eye and gatifloxacin in the other. Measurements of corneal sensitivity were recorded at baseline and at the two evaluatory visits (Day 7 and 14). A Cochet‐Bonnet aesthesiometer was used to determine corneal sensitivity, as an indicator of any potential ocular neuropathic effects. Results Ninety two subjects completed the study. No significant differences in corneal sensitivity for moxifloxacin, gatifloxacin, or placebo‐treated eyes were evident at Day 7 or Day 14 as compared to baseline. Similarly, there were no significant differences in corneal sensitivity measurements between the two fluoroquinolones. Conclusions Though peripheral neuropathies have been reported with use of systemic fluoroquinolones, this does not appear to be the case with ophthalmic fluoroquinolone formulations.